London, March 24, 2011 - The biotech company Farsight Bioscience Ltd.

announces the appointment of Dr.

Dimitris Tsoukalas to its Scientific Advisory Board (SAB).

As a well-known expert on primary health care, Dr.

Tsoukalas’s medical experience will be a great asset to the company.

The SAB works closely with the company to support development of the Farsight product pipeline. Dr.

Tsoukalas graduated from the Medical School of Universita degli Studi di Napoli Federico II in 1991.

Five years later, in 1996, he post-graduated in Copenhagen, Denmark on communication skills, management and Human Resources.

In 2001 he completed his specialty in General and Family Medicine at the University Hospital Hipokrateio in Athens.

And in 2003 he post-graduated at the National Center of Public Administration on the Administration of Health Services.

2004 was the year when Dr.

Tsoukalas received award and Honorable Mention from the Greek Ministry of Health for his contribution to Primary Health.

He served as Primary Health Care Clinic Director in the National Health System of Greece.

During that period Tsoukalas personally examined 60,000 cases while also supervising 250,000 more cases with his medical team.

In 2006 he assumed the post of General Director of Detox Centers International.

Dr.

Tsoukalas has received numerous honorable distinctions for his contribution on community matters and preventive medicine in Greece.

He has spoken on Greek national TV for matters concerning health, nutrition, prevention and environmental medicine as well as participated in numerous medical and scientific conventions in Greece and abroad.

He is a member of the Athens Medical Association, American Obesity Society, International Academy of Detoxification Specialists, American Holistic Medicine Association and Nutrition for Optimal Health Association.

“We are so happy to welcome Dr.

Tsoukalas as a member of our Scientific Advisory Board”, states Erling Refsum, Chief Executive Officer of Farsight: “Thanks to our remuneration agreement we can draw on his vast expertise within primary health care at least until the end of 2012.” “You can be sure that I am equally happy to get the opportunity to enter into such a strong group of medical experts”, says Dr.

Dimitris Tsoukalas: “I look forward to working with my fellow board members, and I guarantee you that I will do my utmost to live up to your expectations - and contribute to the continuous growth of this promising company.”
About Farsight Bioscience Limited Farsight Bioscience’s core activities centre on developing drugs in large markets with significant growth that offer the potential to become blockbusters.

Its focus is on primary care drugs for the prevention and treatment of human diseases.

So far three indication areas that satisfy these criteria have been identified: Metabolic Disorders (Obesity and Diabetes-2); inflammatory diseases (arthritis, bowel diseases); cardiovascular (anti-atherosclerotic and anti-inflammatory).

Through the use of outsourcing and strategic partnerships Farsight runs a lean as well as cost and time-efficient drug development engine.

The objective is to exit any research project as soon as a commercially viable exit is found.

The intention is to collaborate with other biotech entities to share research and cost.

Also, the aim is to create value through being cost and time-efficient as well as industrious and systematic, operating on the prime spot of value creation between drug discovery and phase III clinical studies.

The Company’s mission is to make safe and effective drugs available to the public, quickly and at affordable prices. See also: www.farsightbioscience.com. For further information: Farsight Bioscience Limited 29 Harley Street London, W1G 9QR England Telephone: +49 30 3674 0558 Email:
Disclaimer – forward-looking statements The Farsight Bioscience Limited communications contains certain statements regarding future events that express the beliefs and expectations of management.

Such statements are based on current expectations, estimates and forecasts on the part of company management and imply various known and unknown risks and uncertainties, which may result in actual earnings, the financial situation, growth or performance to be different from the estimates expressed or implied in the forward-looking statements.

Farsight is of the opinion that the expectations reflected in the forward-looking statements are appropriate.

However, it cannot guarantee that these expectations will materialize.

Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ from those projected in the forward-looking statements, including the risks that actual results may differ from those projected in the forward-looking statements.

Projected events in this press release may not occur due to unforeseen circumstances, various factors, and other risks.

Farsight Bioscience Limited does not assume any obligation to update these forward-looking statements or adapt them to future events and developments.
NEWSLETTER REGISTRIERUNG: Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach: http://www.irw-press.com/alert_subscription.php?lang=en&isin=GB00B60Q3R70 Mitteilung übermittelt durch IRW-Press.com.

Für den Inhalt ist der Aussender verantwortlich.

Kostenloser Abdruck mit Quellenangabe erlaubt.